Department of Gastroenterology, Shanghai East Hospital affiliated to Tongji University, Shanghai, China.
Department of Gastroenterology, the 928th Hospital of the PLA Joint Logistics Support Force, Haikou, Hainan, China.
JCI Insight. 2021 Jul 22;6(14):e150052. doi: 10.1172/jci.insight.150052.
BackgroundAbdominal pain and constipation are 2 main symptoms in patients with constipation-predominant irritable bowel syndrome (IBS-C). This study aimed to investigate the effects and possible mechanisms of transcutaneous auricular vagal nerve stimulation (taVNS) in patients with IBS-C.MethodsForty-two patients with IBS-C were randomized into a 4-week sham-taVNS or taVNS treatment. The primary outcomes were complete spontaneous bowel movements per week (CSBMs/week) and visual analog scale (VAS) for abdominal pain. High-resolution anorectal manometry (HRAM) was performed to evaluate anorectal motor and sensory function. Cytokines and brain gut peptides were analyzed in blood samples. ECG was recorded for the assessment of autonomic function.ResultsCompared with sham-taVNS, (a) taVNS increased CSBMs/week (P = 0.001) and decreased VAS pain score (P = 0.001); (b) improved quality of life (P = 0.020) and decreased IBS symptom score (P = 0.001); (c) improved rectoanal inhibitory reflex (P = 0.014) and improved rectal sensation (P < 0.04); (d) decreased a number of proinflammatory cytokines and serotonin in circulation; and (e) enhanced vagal activity (P = 0.040). The vagal activity was weakly correlated with the CSBMs/week (r = 0.391; P = 0.010) and the VAS pain score (r = -0.347; P = 0.025).ConclusionsNoninvasive taVNS improves both constipation and abdominal pain in patients with IBS-C. The improvement in IBS-C symptoms might be attributed to the integrative effects of taVNS on intestinal functions mediated via the autoimmune mechanisms.Trial registrationwww.chictr.org.cn, no. ChiCTR2000029644.FundingNational Natural Science Foundation of China (grant no. 81970538 for FL).
背景:腹痛和便秘是便秘型肠易激综合征(IBS-C)患者的 2 种主要症状。本研究旨在探讨经皮耳迷走神经刺激(taVNS)对 IBS-C 患者的影响及其可能机制。
方法:42 例 IBS-C 患者随机分为 4 周 sham-taVNS 或 taVNS 治疗。主要结局是每周完全自发排便次数(CSBMs/周)和腹痛视觉模拟评分(VAS)。高分辨率肛门直肠测压(HRAM)用于评估肛门直肠运动和感觉功能。分析血液样本中的细胞因子和脑肠肽。记录心电图以评估自主神经功能。
结果:与 sham-taVNS 相比,(a)taVNS 增加 CSBMs/周(P=0.001)和降低 VAS 疼痛评分(P=0.001);(b)改善生活质量(P=0.020)和降低 IBS 症状评分(P=0.001);(c)改善直肠肛门抑制反射(P=0.014)和改善直肠感觉(P<0.04);(d)降低循环中促炎细胞因子和 5-羟色胺的数量;(e)增强迷走神经活动(P=0.040)。迷走神经活动与 CSBMs/周(r=0.391;P=0.010)和 VAS 疼痛评分(r=-0.347;P=0.025)呈弱相关。
结论:非侵入性 taVNS 可改善 IBS-C 患者的便秘和腹痛症状。IBS-C 症状的改善可能归因于 taVNS 通过自身免疫机制对肠道功能的综合作用。
试验注册:www.chictr.org.cn,注册号 ChiCTR2000029644。
基金:国家自然科学基金(FL 资助号 81970538)。
Am J Physiol Gastrointest Liver Physiol. 2021-5-1
J Transl Gastroenterol. 2025-6
Front Endocrinol (Lausanne). 2025-3-27
Front Pain Res (Lausanne). 2025-1-17
Gastroenterol Rep (Oxf). 2025-1-26
Front Neurol. 2024-12-10
Am J Physiol Gastrointest Liver Physiol. 2021-5-1
JACC Clin Electrophysiol. 2020-3
Am J Physiol Gastrointest Liver Physiol. 2020-2-18
Am J Physiol Gastrointest Liver Physiol. 2020-1-27